The document is a regulatory filing containing the transcript of the Q4 FY26 Earnings Conference Call held on May 21, 2026. The call was conducted to discuss the company's financial and operational performance for the quarter and year ended March 31, 2026.
The event was scheduled after the earnings announcement. The call began at an unspecified time, and the earnings presentation was uploaded to the stock exchanges and the company's website (www.gmmpfaudler.com) on the day of the call.
The stated purpose of the event was to provide a brief overview of the company's performance and to address questions from analysts.
Management participants included:
Mr. Tarak Patel – Managing Director
Mr. Gregory Gelhaus – Group Chief Executive Officer
Mr. Alexander Poempner – Group Chief Financial Officer
Mr. Ankit Nayyar – Deputy Chief Financial Officer
Ms. Mittal Mehta- Company Secretary
Mr. Raveen Kanabar – Manager Finance & Accounts
The earnings presentation was made available on the company's website. A transcript of the call was filed with the exchanges and is also available on the website.
The call began with a standard disclaimer that the discussions contained forward-looking statements subject to risks and uncertainties.
FY26 Performance: Revenue increased by approximately 10% Year-on-Year (YoY). EBITDA grew by approximately 11% YoY. EBITDA margins remained stable for the year.
India Business Performance: Revenue grew 12% YoY. EBITDA grew 24% YoY. Profit After Tax (PAT) grew 40% YoY.
Order Intake: Strong order intake in Q4. Full-year order intake was INR 3,714 crores, up 20% YoY from INR 3,100 crores in the previous year.
Order Backlog: The opening order backlog as of April 1 was up 34% YoY, providing strong revenue visibility.
Business Environment: Noted a difficult global economic environment over the last 6-9 months, with recent uncertainties from the Middle East conflict. The traditional chemical segment remains slow, while pharma has performed well.
Diversification Strategy: Nearly 50% of the year's order intake came from non-traditional industries (non-chemical and non-pharma), including semiconductors, defence, oil and gas, petrochemicals, and metals and minerals.
Restructuring & Cost Savings: A restructuring initiative in Germany resulted in an additional exceptional cost of INR 9 crores but is expected to yield annual cost savings of INR 45 crores. Facilities in the UK and Hyderabad, India, were shut down. The Poland facility is operational as a low-cost source for Europe.
Cash Flow & Debt: Generated strong free cash flow of INR 367 crores (Free Cash Flow to EBITDA ratio slightly above 90%). Repaid long-term debt of INR 60 crores. Net debt to adjusted EBITDA ratio improved to 0.4x from 0.5x. Net debt to equity is 0.1x.
Taxation & Finance Costs: A high effective tax rate persists, primarily due to issues with a Luxembourg entity and an intercompany loan creating FX exposure. Management is working on restructuring the financing setup to improve the flow-through from EBITDA to PAT.
Outlook: Management expressed confidence in improvement for FY27 due to the strong backlog and cost-saving measures but refrained from providing specific guidance due to geopolitical uncertainties and the multi-year conversion timeline for large systems orders. A three-year strategic plan is prepared, with details expected to be shared with the market in the next few quarters.
Margin Target: The company aspires to achieve a sustainable EBITDA margin of 15% in the medium term.
Additional Notes Section
The document is an enclosure to a formal regulatory submission letter dated May 28, 2026, signed by the Company Secretary, Mittal Mehta.
The enclosure was the full transcript of the earnings conference call.
No new financial data was disclosed in the announcement letter itself; all figures were discussed within the enclosed transcript.
